Carfilzomib is primarily indicated for patients with relapsed or refractory multiple myeloma who have received one or more prior therapies. It is often used in combination with other medications such as dexamethasone and lenalidomide to enhance its efficacy. Clinical trials have shown significant improvements in overall survival and progression-free survival when carfilzomib is incorporated into treatment regimens.
